Skip to Content

Purixan Approval History

  • FDA approved: Yes (First approved April 28th, 2014)
  • Brand name: Purixan
  • Generic name: mercaptopurine
  • Dosage form: Oral Suspension
  • Company: Nova Laboratories, Ltd.
  • Treatment for: Acute Lymphoblastic Leukemia

Purixan (mercaptopurine) is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia.

Development History and FDA Approval Process for Purixan

Apr 29, 2014Approval FDA Approves Purixan (mercaptopurine) Oral Suspension

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.